Drug or treatment

Elranatamab clinical trials

• 25Clinical trials
• 36Countries

Newest trials

All recruiting trials (25)

• Elranatamab consolidation for newly diagnosed plasmablastic lymphoma

  This study tests whether giving Elranatamab after initial chemotherapy can help patients with plasmablastic lymphoma, with or without HIV, stay in remission.

  Recruiting Phase 1 University of Illinois Chicago · Chicago, Illinois · NCT07647432

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Elranatamab plus cyclophosphamide for relapsed/refractory multiple myeloma with high-risk features

  This will test whether adding cyclophosphamide to elranatamab helps people with relapsed or refractory multiple myeloma who have risk factors that might make elranatamab alone less effective.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07454382

• Low-dose radiation to boost elranatamab for relapsed/refractory multiple myeloma with extramedullary or paramedullary disease

  We will test whether low-dose radiation given before elranatamab helps people with relapsed or refractory multiple myeloma that has grown outside the bone or into surrounding tissue respond better to treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07382739

• Cemsidomide plus elranatamab for relapsed or refractory multiple myeloma

  This will try giving cemsidomide pills together with elranatamab injections to see if the combination is safe and helps people with relapsed or refractory multiple myeloma.

  Recruiting at 12 sites Phase 1 C4 Therapeutics, Inc. · Gilbert, Arizona and 18 other locations · NCT07280013

• Elranatamab with lenalidomide and dexamethasone for newly diagnosed multiple myeloma.

  This trial will test whether adding elranatamab to lenalidomide and dexamethasone helps people newly diagnosed with multiple myeloma.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06997081

• Mezigdomide plus elranatamab for relapsed or refractory multiple myeloma

  This test tries adding mezigdomide to elranatamab (with dexamethasone) to see if it is safe and can help adults with relapsed or refractory multiple myeloma who have had 1–4 prior treatments (eligibility differs by phase).

  Recruiting at 20 sites Phase 1/2 Celgene · Birmingham, Alabama and 21 other locations · NCT06988488

• Elranatamab treatment after cilta-cel for high-risk relapsed myeloma patients

  This study is testing if Elranatamab can help high-risk myeloma patients who have already had cilta-cel live longer without their disease getting worse.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06947083

• Letermovir to prevent CMV in relapsed/refractory multiple myeloma patients on elranatamab

  This trial tests whether the antiviral letermovir can prevent clinically significant CMV infections in adult CMV‑seropositive patients with relapsed or refractory multiple myeloma who are receiving elranatamab.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT06920251

• Elranatamab plus lenalidomide after D-VRd and transplant for transplant-eligible newly diagnosed multiple myeloma

  This trial will test whether adding elranatamab with lenalidomide after D-VRd induction and transplant, and using elranatamab for maintenance, helps people with newly diagnosed, transplant-eligible multiple myeloma stay in remission longer than standard lenalidomide.

  Recruiting at 64 sites Phase 3 Intergroupe Francophone du Myelome · Brussels and 68 other locations · NCT06918002

• Elranatamab plus under-the-skin isatuximab for relapsed/refractory multiple myeloma

  This trial will test whether combining elranatamab with subcutaneous isatuximab helps people with relapsed or refractory multiple myeloma who have had at least two prior therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06832865

• Personalized dendritic cell–myeloma fusion vaccine combined with elranatamab for relapsed or refractory multiple myeloma

  This will try a personalized dendritic cell–myeloma fusion vaccine given with elranatamab in people with relapsed or refractory multiple myeloma.

  Recruiting at 2 sites Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts and 1 other locations · NCT06799026

• Evaluating elranatamab for treating relapsed or refractory multiple myeloma

  This study is testing a new treatment called elranatamab to see if it can help people with relapsed or refractory multiple myeloma who have already tried other therapies.

  Recruiting Phase 2 University of California, San Diego · La Jolla, California · NCT06711705

• Combination of mezigdomide and elranatamab for treating relapsed multiple myeloma

  This study is testing a new combination treatment of mezigdomide and elranatamab for people with relapsed multiple myeloma to see how well it works and how safe it is.

  Recruiting at 6 sites Phase 1/2 Seoul National University Hospital · Singapore and 6 other locations · NCT06645678

• Evaluating elranatamab for patients with relapsed or refractory AL amyloidosis

  This study is testing a new treatment called elranatamab to see if it can help people with relapsed or refractory AL amyloidosis feel better and manage their condition.

  Recruiting at 5 sites Phase 1/2 Dana-Farber Cancer Institute · New Haven, Connecticut and 4 other locations · NCT06569147

• Personalized maintenance treatment for multiple myeloma after stem cell transplant

  This study tests a personalized treatment plan using a new immunotherapy drug for people with multiple myeloma after a stem cell transplant to see if it helps them stay in remission longer.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT06483100

• Outpatient treatment with elranatamab for relapsed multiple myeloma

  This study is testing a new treatment called elranatamab for people with relapsed multiple myeloma to see if it can be safely given at home and help improve their health without needing to stay in the hospital.

  Recruiting at 6 sites Phase 2 Ontario Clinical Oncology Group (OCOG) · Vancouver, British Columbia and 5 other locations · NCT06421675

• Using elranatamab before and after stem cell transplant for high-risk multiple myeloma

  This study is testing if the drug elranatamab can help people with high-risk multiple myeloma by giving it before and after a stem cell transplant to see if it improves their chances of staying cancer-free.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06207799

• Evaluating Elranatamab for Relapsed Multiple Myeloma

  This study tests if a new treatment called elranatamab can help people with relapsed multiple myeloma feel better compared to standard therapies they might have already tried.

  Recruiting at 222 sites Phase 3 Pfizer · Mobile, Alabama and 269 other locations · NCT06152575

• Using elranatamab to treat relapsed/refractory multiple myeloma

  This study is testing if a new drug called elranatamab can help people with tough-to-treat multiple myeloma feel better and keep their disease from getting worse.

  Recruiting at 3 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06138275

• Access to Elranatamab for Multiple Myeloma Patients

  This study is providing continued access to the treatment elranatamab for people with Multiple Myeloma who have already seen benefits from it in earlier trials.

  Recruiting at 31 sites Phase 4 Pfizer · Irvine, California and 32 other locations · NCT06057402

• Self-administration of Elranatamab for multiple myeloma at home

  This study is testing if patients with relapsed multiple myeloma can safely give themselves a new treatment called Elranatamab at home and how it affects their quality of life.

  Recruiting at 2 sites Phase 2 Odense University Hospital · Odense and 1 other locations · NCT06015542

• Evaluating a new combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of two treatments for people with relapsed or refractory multiple myeloma to see if it's safe and how well it works.

  Recruiting at 14 sites Phase 1 Genentech, Inc. · Camperdown, New South Wales and 13 other locations · NCT05927571

• Evaluating new treatment combinations for newly diagnosed multiple myeloma patients not eligible for transplant

  This study is testing different combinations of medications for people with newly diagnosed multiple myeloma who can't have a transplant to see which one works best and is safest.

  Recruiting at 170 sites Phase 3 Pfizer · Daphne, Alabama and 179 other locations · NCT05623020

• Elranatamab alone or with daratumumab for people with multiple myeloma after prior treatment

  This trial will test whether the BCMA-targeting drug elranatamab alone or together with daratumumab helps people with multiple myeloma who have already been treated with lenalidomide, compared with daratumumab plus pomalidomide and dexamethasone.

  Recruiting at 80 sites Phase 3 Pfizer · Clovis, California and 236 other locations · NCT05020236

Quick answers

How many clinical trials of Elranatamab are recruiting right now?

25, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 36 countries. The most sites are in United States (19 trials), South Korea (6 trials), Canada (6 trials), Australia (5 trials), Spain (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 1: 4, Phase 3: 4, Phase 1/2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →